Ads
related to: denosumab osteoporosis side effects women postmenopausalwiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [11] [12] The most common side effects are joint and muscle pain in the arms or legs. [13]
Servier states that the use is now restricted to treatment of severe osteoporosis in postmenopausal women at high risk for fracture. [2] The European Pharmacovigilance Risk Assessment Committee (PRAC) recommended restriction in the use of strontium ranelate, based on a routine benefit-risk assessment of the medicine, which included data showing ...
Raloxifene increases bone mineral density in postmenopausal women but decreases it in premenopausal women. [14] In the MORE trial, the risk of vertebral fractures was decreased by 30%, and bone mineral density was increased in the spine (by 2.1% at 60 mg, 2.4% at 120 mg) and femoral neck (2.6% at 60 mg, 2.7% at 120 mg). [ 20 ]
Bazedoxifene is used for treatment of osteoporosis in postmenopausal women at increased risk of fracture. It has been shown to be relatively safe and well-tolerated. It shows no breast or endometrial stimulation and in the first two years the small increase is better in venous thromboembolism, and similar in the long term to other SERMs.
In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...
As women begin to hit perimenopause and menopause, some start to question their identity, struggle with big life stressors like caring for aging parents, divorce, age discrimination at work, and ...
Particular medications can result in MRONJ, a serious but uncommon side effect in certain individuals. Such medications are frequently used to treat diseases that cause bone resorption such as osteoporosis, or to treat cancer. The main groups of drugs involved are anti-resorptive drugs, and anti-angiogenic drugs.
Osteoporosis can affect nearly 1 in 3 women and the bone loss is the most rapid within the first 2–3 years after menopause. This can be prevented by menopause hormone therapy or MHT, which is meant to prevent bone loss and the degradation of the bone microarchitecture and is noted to reduce the risk of fractures in bones by 20-30%.